Emtricitabine (BW 1592) - Moligand™, 10mM in DMSO , Human immunodeficiency virus type 1 reverse transcriptase inhibitor, CAS No.143491-57-0, Human immunodeficiency virus type 1 reverse transcriptase inhibitor

CAS: 143491-57-0 Cat. No.: E408866 Molecular Weight: 247.25 EC Number: 604-363-1

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

FTC | 4-​amino-​5-​fluoro-​1-​[(2R,​5S)​-​2-​(hydroxymethyl)​-​1,​3-​oxathiolan-​5-​yl]​-2(1H)​-​pyrimidinone

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Emtricitabine (BW 1592) Emtricitabine (BW1592, FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
In vitro

Emtricitabine moderately reduces hepatocyte proliferation independent of effects on mtDNA in HepG2 human hepatoma cells. Emtricitabine plus tenofovir slightly reduced cell proliferation without affecting mitochondrial parameters. Emtricitabine efficiently converts to their active metabolites in PBMCs and CEM cells. Emtricitabine combined with Tenofovir displays additive to synergistic activity against HIV replication in PBMCs and results in strongly synergistic anti-HIV activity in MT-2 cells against both wild-type and mutant virus. Emtricitabine demonstrates antiviral activity against laboratory adapted strains of HIV-1 and HIV-2 in various cell system. Emtricitabine also exhibits antiviral activity in cell culture against feline and simian immuno-deficiency viruses (SIVs). Emtricitabine consistently exhibits up to 10-fold greater activity than lamivudine against all viruses tested in all T-cell lines. Emtricitabine generally demonstrates greater potency in vitro in human PBMCs than in MT-4 lines. Emtricitabine also exhibits anti-HBV activity in vitro (EC50, 0.01–0.04 µM) that is comparable to the anti-HBV activity of 3TC. Emtricitabine is approximately fourfold more active than 3TC in assays in the transformed T-cell line MT-4 infected with HIV-(1IIIB), whereas Zidovudine is more active than Emtricitabine. Emtricitabine, Lamivudine and Zidovudine are equally active against a panel of eight primary HIV-1 isolates from antiretroviral-naive subjects in PBMCs.

In vivo

Cell Data

cell lines：Erythroid cells

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Synonyms

FTC | 4-​amino-​5-​fluoro-​1-​[(2R, ​5S)​-​2-​(hydroxymethyl)​-​1, ​3-​oxathiolan-​5-​yl]​-2(1H)​-​pyrimidinone

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

Emtricitabine (BW1592, FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

INHIBITOR

Mechanism of action

Human immunodeficiency virus type 1 reverse transcriptase inhibitor

Names and Identifiers

• Isomeric SMILES: C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
• Molecular Weight: 247.25
• Reaxy-Rn: 11732976
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=11732976&ln=

Chemical and Physical Properties

• Specific Rotation[α]: -140° (C=0.25,MeOH)
• Melt Point(°C): 155 °C

References

1. Liu Youhua, Liu Jiaqi, Ren Ruiti, Xin Zimeng, Luo Yaojun, Chen Yushi, Huang Chaoqun, Liu Yuxi, Yang Tongyudan, Wang Xinxia.  (2025)  Short-term and long-term high-fat diet promote metabolic disorder through reprogramming mRNA m6A in white adipose tissue by gut microbiota.  Microbiome,  13  (1): (1-17).  [PMID:40091072] [10.1186/s40168-025-02047-4]

2. Haoran Wang, Tong Xu, Shuaishuai Xin, Guocheng Liu, Qinghua Yan, Dong Ma, Yanlong Sun, Chengzhi Zhou, Yanjun Xin, Ya-nan Zhang.  (2025)  Nucleoside structure promotes the degradation of antiviral drugs in simulated sunlight-activated periodate system.  SEPARATION AND PURIFICATION TECHNOLOGY,      [PMID:] [10.1016/j.seppur.2025.133922]